These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 23529786)

  • 1. Oral availability of bilastine.
    Sádaba B; Gómez-Guiu A; Azanza JR; Ortega I; Valiente R
    Clin Drug Investig; 2013 May; 33(5):375-81. PubMed ID: 23529786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioequivalence Evaluation of Three Pediatric Oral Formulations of Bilastine in Healthy Subjects: Results from a Randomized, Open Label, Crossover Study.
    Sádaba B; Azanza JR; García-Bea A; Labeaga L; Campo C; Valiente R
    Eur J Drug Metab Pharmacokinet; 2020 Apr; 45(2):265-272. PubMed ID: 31820304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and safety of bilastine in children aged 6 to 11 years with allergic rhinoconjunctivitis or chronic urticaria.
    Rodríguez M; Vozmediano V; García-Bea A; Novák Z; Yáñez A; Campo C; Labeaga L
    Eur J Pediatr; 2020 May; 179(5):801-805. PubMed ID: 31919579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, Pharmacodynamics and Population Pharmacokinetic/Pharmacodynamic Modelling of Bilastine, a Second-Generation Antihistamine, in Healthy Japanese Subjects.
    Togawa M; Yamaya H; Rodríguez M; Nagashima H
    Clin Drug Investig; 2016 Dec; 36(12):1011-1021. PubMed ID: 27498100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety profile of bilastine: 2nd generation H1-antihistamines.
    Scaglione F
    Eur Rev Med Pharmacol Sci; 2012 Dec; 16(14):1999-2005. PubMed ID: 23242729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concentration analysis.
    Tyl B; Kabbaj M; Azzam S; Sologuren A; Valiente R; Reinbolt E; Roupe K; Blanco N; Wheeler W
    J Clin Pharmacol; 2012 Jun; 52(6):893-903. PubMed ID: 21642470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bilastine: a new antihistamine with an optimal benefit-to-risk ratio for safety during driving.
    Jáuregui I; Ramaekers JG; Yanai K; Farré M; Redondo E; Valiente R; Labeaga L
    Expert Opin Drug Saf; 2016 Jan; 15(1):89-98. PubMed ID: 26571227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study.
    Kuna P; Bachert C; Nowacki Z; van Cauwenberge P; Agache I; Fouquert L; Roger A; Sologuren A; Valiente R;
    Clin Exp Allergy; 2009 Sep; 39(9):1338-47. PubMed ID: 19438584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical toxicity profile of oral bilastine.
    Lucero ML; Arteche JK; Sommer EW; Casadesus A
    Drug Chem Toxicol; 2012 Jun; 35 Suppl 1():25-33. PubMed ID: 22616813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bilastine vs. hydroxyzine: occupation of brain histamine H1 -receptors evaluated by positron emission tomography in healthy volunteers.
    Farré M; Pérez-Mañá C; Papaseit E; Menoyo E; Pérez M; Martin S; Bullich S; Rojas S; Herance JR; Trampal C; Labeaga L; Valiente R
    Br J Clin Pharmacol; 2014 Nov; 78(5):970-80. PubMed ID: 24833043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the single-dose pharmacokinetics of bilastine in subjects with various degrees of renal insufficiency.
    Lasseter KC; Sologuren A; La Noce A; Dilzer SC
    Clin Drug Investig; 2013 Sep; 33(9):665-73. PubMed ID: 23873362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bilastine: a new nonsedating oral H1 antihistamine for treatment of allergic rhinoconjunctivitis and urticaria.
    Wolthers OD
    Biomed Res Int; 2013; 2013():626837. PubMed ID: 23956994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation.
    Ochoa D; Román M; Belmonte C; Martín-Vilchez S; Mejía-Abril G; Abad-Santos F; Hernández G; Arranz P; Elgezabal L; Fernández N
    Adv Ther; 2021 Jul; 38(7):4070-4081. PubMed ID: 34125400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine.
    Jauregizar N; de la Fuente L; Lucero ML; Sologuren A; Leal N; Rodríguez M
    Clin Pharmacokinet; 2009; 48(8):543-54. PubMed ID: 19705924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bilastine for the relief of allergy symptoms.
    Sádaba Díaz de Rada B; Azanza Perea JR; Gomez-Guiu Hormigos A
    Drugs Today (Barc); 2011 Apr; 47(4):251-62. PubMed ID: 21573249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Model-informed pediatric development applied to bilastine: Analysis of the clinical PK data and confirmation of the dose selected for the target population.
    Vozmediano V; Lukas JC; Encinas E; Schmidt S; Sologuren A; Valiente R; Labeaga L; Campo C; Rodriguez M
    Eur J Pharm Sci; 2019 Feb; 128():180-192. PubMed ID: 30468868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of bilastine in Japanese patients with chronic spontaneous urticaria: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II/III study.
    Hide M; Yagami A; Togawa M; Saito A; Furue M
    Allergol Int; 2017 Apr; 66(2):317-325. PubMed ID: 27599913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bilastine: a new H
    Church MK; Labeaga L
    J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1447-1452. PubMed ID: 28467671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-year safety and efficacy study of bilastine treatment in Japanese patients with chronic spontaneous urticaria or pruritus associated with skin diseases.
    Yagami A; Furue M; Togawa M; Saito A; Hide M
    J Dermatol; 2017 Apr; 44(4):375-385. PubMed ID: 27862227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bilastine safety in drivers who need antihistamines: new evidence from high-speed simulator driving test on allergic patients.
    Demonte A; Guanti MB; Liberati S; Biffi A; Fernando F; Fainello M; Pepe P
    Eur Rev Med Pharmacol Sci; 2018 Feb; 22(3):820-828. PubMed ID: 29461615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.